Rhein Biotech (Maastricht, The Neth...
Rhein Biotech (Maastricht, The Netherlands) and Corixa Corporation (Seattle, WA) have announced the rises of a Phase 3 trial of a novel two-dose hepatitis B vaccine. The vaccine is based upon Rhein Biotech's Hansenula polymorpha yeast-based recombinant hepatitis B antigen and Corixa's RC-529 synthetic adjuvant. Commercially available hepatitis B vaccines, which are all based onward Rhein Biotech's antigen, require
|